Tech Center 1600 • Art Units: 1613 1614 1621 1629 1644
This examiner grants 75% of resolved cases
Kevin E. Weddington is an examiner in Tech Center 1600, specifically Art Unit 1613. His professional record includes 1473 resolved cases, which is an exceptionally large data set. The allowance rate for Weddington is 75.2 percent, indicating that a high percentage of applications result in a patent grant. This rate provides a strong expectation of success for practitioners in this unit.
The interview lift for Weddington is 9.8 percent. This positive lift indicates that direct communication is a beneficial strategy, even with an already high allowance rate of 75.2 percent. While the lift is more modest than some other examiners, it still suggests that interviews are a productive way to resolve remaining issues in the 1473 resolved cases. Practitioners should consider this a useful tactical option in Art Unit 1613.
The median days to allowance is 903. This timeline is relatively efficient for reaching a final resolution. The combination of a 903-day median and a 75.2 percent allowance rate makes Art Unit 1613 a favorable environment for patent prosecution. The large volume of cases ensures that these metrics are a reliable reflection of Weddington's long-term examination tendencies within Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19684927 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Non-Final OA | ANTECIP BIOVENTURES II LLC |
| 18591870 | POLYAMINO IODINATED COMPOUNDS AND RADIOPAQUE HYDROGELS FORMED THEREFROM | Non-Final OA | Boston Scientific Scimed, Inc. |
| 18043436 | N-Linked Glycosylation Inhibitors and Methods of Using Same | Non-Final OA | YALE UNIVERSITY |
| 18217821 | LIPID EMULSIONS FOR PARENTERAL NUTRITION | Non-Final OA | BAXTER HEALTHCARE SA |
| 18251827 | PHARMACEUTICAL COMPOSITION FOR TREATING LEUKEMIA COMPRISING FLT3 INHIBITOR | Final Rejection | HANMI PHARM. CO., LTD. |
| 18818701 | TRICYCLIC COMPOUNDS | Non-Final OA | Jacobio Pharmaceuticals Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy